WO2003072046A3 - Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances - Google Patents

Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances Download PDF

Info

Publication number
WO2003072046A3
WO2003072046A3 PCT/US2003/005525 US0305525W WO03072046A3 WO 2003072046 A3 WO2003072046 A3 WO 2003072046A3 US 0305525 W US0305525 W US 0305525W WO 03072046 A3 WO03072046 A3 WO 03072046A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained release
controlled substances
release pharmaceutical
pharmaceutical compounds
prevent abuse
Prior art date
Application number
PCT/US2003/005525
Other languages
French (fr)
Other versions
WO2003072046A2 (en
Inventor
Thomas Piccariello
Randal J Kirk
Original Assignee
New River Pharmaceuticals Inc
Thomas Piccariello
Randal J Kirk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New River Pharmaceuticals Inc, Thomas Piccariello, Randal J Kirk filed Critical New River Pharmaceuticals Inc
Priority to KR1020047013136A priority Critical patent/KR100822498B1/en
Priority to CA2740256A priority patent/CA2740256A1/en
Priority to IL16366703A priority patent/IL163667A0/en
Priority to JP2003570793A priority patent/JP4878732B2/en
Priority to ES03716144.5T priority patent/ES2500117T3/en
Priority to EP03716144.5A priority patent/EP1531844B1/en
Priority to CA2477004A priority patent/CA2477004C/en
Priority to AU2003219863A priority patent/AU2003219863C1/en
Publication of WO2003072046A2 publication Critical patent/WO2003072046A2/en
Priority to US10/858,526 priority patent/US7105486B2/en
Priority to IL163667A priority patent/IL163667A/en
Priority to US10/923,257 priority patent/US7622441B2/en
Priority to US10/953,116 priority patent/US7375082B2/en
Priority to US10/953,111 priority patent/US20070066537A1/en
Publication of WO2003072046A3 publication Critical patent/WO2003072046A3/en
Priority to US11/089,056 priority patent/US20060014697A1/en
Priority to US11/179,801 priority patent/US8133881B2/en
Priority to US11/400,304 priority patent/US7700561B2/en
Priority to US12/131,923 priority patent/US7659253B2/en
Priority to US12/201,794 priority patent/US7687466B2/en
Priority to US12/201,820 priority patent/US20090137673A1/en
Priority to US12/201,866 priority patent/US7662788B2/en
Priority to US12/202,067 priority patent/US7687467B2/en
Priority to US12/201,760 priority patent/US7655630B2/en
Priority to US12/201,950 priority patent/US7671030B2/en
Priority to US12/201,907 priority patent/US7713936B2/en
Priority to US12/202,146 priority patent/US7678771B2/en
Priority to US12/201,982 priority patent/US7674774B2/en
Priority to US12/202,003 priority patent/US7723305B2/en
Priority to US12/202,159 priority patent/US7671031B2/en
Priority to US12/201,586 priority patent/US7659254B2/en
Priority to US12/201,739 priority patent/US7678770B2/en
Priority to US12/202,096 priority patent/US7718619B2/en
Priority to US12/202,955 priority patent/US20090143305A1/en
Priority to US12/203,137 priority patent/US20090149392A1/en
Priority to US12/203,133 priority patent/US20090137490A1/en
Priority to US12/202,845 priority patent/US20090137486A1/en
Priority to US12/202,987 priority patent/US20090192093A1/en
Priority to US12/231,489 priority patent/US20090143307A1/en
Priority to US12/203,058 priority patent/US20090143306A1/en
Priority to US12/203,132 priority patent/US20090137489A1/en
Priority to US12/203,129 priority patent/US20090137488A1/en
Priority to US12/203,134 priority patent/US20090137491A1/en
Priority to US12/202,699 priority patent/US20090131322A1/en
Priority to US12/202,777 priority patent/US20090143304A1/en
Priority to US12/202,941 priority patent/US20090137487A1/en
Priority to US12/203,127 priority patent/US20090131332A1/en
Priority to US12/203,136 priority patent/US20090209471A1/en
Priority to US12/203,108 priority patent/US20090181898A1/en
Priority to US12/239,479 priority patent/US20090131334A1/en
Priority to US12/239,180 priority patent/US20090186825A1/en
Priority to US12/239,577 priority patent/US20090131326A1/en
Priority to US12/239,364 priority patent/US20090137515A1/en
Priority to US12/239,247 priority patent/US20090131333A1/en
Priority to US12/239,600 priority patent/US20090137677A1/en
Priority to US12/239,400 priority patent/US20090186945A1/en
Priority to US12/239,429 priority patent/US20090131476A1/en
Priority to US12/239,087 priority patent/US20090186828A1/en
Priority to US12/239,154 priority patent/US20090131323A1/en
Priority to US12/239,238 priority patent/US20090131325A1/en
Priority to US12/239,221 priority patent/US20090131324A1/en
Priority to US12/239,554 priority patent/US20090131335A1/en
Priority to US12/239,571 priority patent/US20090137461A1/en
Priority to AU2008229978A priority patent/AU2008229978B2/en
Priority to US12/701,483 priority patent/US20110009669A1/en
Priority to US12/756,773 priority patent/US20100197798A1/en
Priority to US12/881,008 priority patent/US8343927B2/en
Priority to US13/339,095 priority patent/US20120115950A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides methods for altering controlled substances in a manner that decreases their potential for abuse. The novel compounds may be combined in tablets with suitable excipients or formulated in solution for oral delivery. When delivered by the oral route the controlled substance is released in a time-dependent manner (sustained release) by acid hydrolysis and/or enzymatic cleavage. When administered by injection the controlled substance is released in a time-dependent manner (sustained release) by way of serum enzymes.
PCT/US2003/005525 2001-08-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances WO2003072046A2 (en)

Priority Applications (66)

Application Number Priority Date Filing Date Title
KR1020047013136A KR100822498B1 (en) 2002-02-22 2003-02-24 Novel Sustained Release Pharmaceutical Compounds to Prevent Abuse of Controlled Substances
CA2740256A CA2740256A1 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
IL16366703A IL163667A0 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to preventabuse of controlled substances
JP2003570793A JP4878732B2 (en) 2002-02-22 2003-02-24 Novel sustained-release pharmaceutical compounds to prevent abuse of controlled substances
ES03716144.5T ES2500117T3 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent the abuse of controlled substances
EP03716144.5A EP1531844B1 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
CA2477004A CA2477004C (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
AU2003219863A AU2003219863C1 (en) 2002-02-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US10/858,526 US7105486B2 (en) 2002-02-22 2004-06-01 Abuse-resistant amphetamine compounds
IL163667A IL163667A (en) 2002-02-22 2004-08-22 Conjugates comprising controlled substances covalently bound to peptides or amino acids and compositions comprising same
US10/923,257 US7622441B2 (en) 2002-02-22 2004-08-23 Sustained release pharmaceutical compounds to prevent abuse of controlled substances
US10/953,116 US7375082B2 (en) 2002-02-22 2004-09-30 Abuse-resistant hydrocodone compounds
US10/953,111 US20070066537A1 (en) 2002-02-22 2004-09-30 Compounds and compositions for prevention of overdose of oxycodone
US11/089,056 US20060014697A1 (en) 2001-08-22 2005-03-25 Pharmaceutical compositions for prevention of overdose or abuse
US11/179,801 US8133881B2 (en) 2003-01-13 2005-07-13 Carbohydrate conjugates to prevent abuse of controlled substances
US11/400,304 US7700561B2 (en) 2002-02-22 2006-04-10 Abuse-resistant amphetamine prodrugs
US12/131,923 US7659253B2 (en) 2002-02-22 2008-06-02 Abuse-resistant amphetamine prodrugs
US12/201,794 US7687466B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,820 US20090137673A1 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,866 US7662788B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,067 US7687467B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,760 US7655630B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,950 US7671030B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,907 US7713936B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,146 US7678771B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,982 US7674774B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,003 US7723305B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,159 US7671031B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,586 US7659254B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/201,739 US7678770B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,096 US7718619B2 (en) 2002-02-22 2008-08-29 Abuse-resistant amphetamine prodrugs
US12/202,955 US20090143305A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,137 US20090149392A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,133 US20090137490A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,845 US20090137486A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,987 US20090192093A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/231,489 US20090143307A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,058 US20090143306A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,132 US20090137489A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,129 US20090137488A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,134 US20090137491A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,699 US20090131322A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,777 US20090143304A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/202,941 US20090137487A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,127 US20090131332A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,136 US20090209471A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/203,108 US20090181898A1 (en) 2002-02-22 2008-09-02 Abuse-resistant amphetamine prodrugs
US12/239,479 US20090131334A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,180 US20090186825A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,577 US20090131326A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,364 US20090137515A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,247 US20090131333A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,600 US20090137677A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,400 US20090186945A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,429 US20090131476A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,087 US20090186828A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,154 US20090131323A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,238 US20090131325A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,221 US20090131324A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,554 US20090131335A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
US12/239,571 US20090137461A1 (en) 2002-02-22 2008-09-26 Abuse-resistant amphetamine prodrugs
AU2008229978A AU2008229978B2 (en) 2002-02-22 2008-10-16 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
US12/701,483 US20110009669A1 (en) 2002-02-22 2010-02-05 Abuse-resistant amphetamine prodrugs
US12/756,773 US20100197798A1 (en) 2002-02-22 2010-04-08 Abuse-resistant amphetamine prodrugs
US12/881,008 US8343927B2 (en) 2001-08-22 2010-09-13 Pharmaceutical compositions for prevention of overdose or abuse
US13/339,095 US20120115950A1 (en) 2002-02-22 2011-12-28 Abuse-resistant amphetamine prodrugs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35836802P 2002-02-22 2002-02-22
US60/358,368 2002-02-22
US36208202P 2002-03-07 2002-03-07
US60/362,082 2002-03-07

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/156,527 Continuation-In-Part US7060708B2 (en) 1999-03-10 2002-05-29 Active agent delivery systems and methods for protecting and administering active agents
US10/923,088 Continuation-In-Part US7427600B2 (en) 2000-08-22 2004-08-23 Active agent delivery systems and methods for protecting and administering active agents

Related Child Applications (8)

Application Number Title Priority Date Filing Date
US10923257 A-371-Of-International 2003-02-24
PCT/US2004/000646 Continuation-In-Part WO2004062614A2 (en) 2003-01-13 2004-01-13 Carbohydrate conjugates to prevent abuse of controlled substances
US10/857,619 Continuation-In-Part US7223735B2 (en) 2002-02-22 2004-06-01 Abuse resistant lysine amphetamine compounds
US10/858,526 Continuation-In-Part US7105486B2 (en) 2002-02-22 2004-06-01 Abuse-resistant amphetamine compounds
US10/858,526 Continuation US7105486B2 (en) 2002-02-22 2004-06-01 Abuse-resistant amphetamine compounds
US10/923,257 Continuation-In-Part US7622441B2 (en) 2001-08-22 2004-08-23 Sustained release pharmaceutical compounds to prevent abuse of controlled substances
US10/923,088 Continuation-In-Part US7427600B2 (en) 2000-08-22 2004-08-23 Active agent delivery systems and methods for protecting and administering active agents
US10/927,257 Continuation-In-Part US7574503B2 (en) 2004-08-27 2004-08-27 Method and system for using abstract classes to extract status information from networked devices

Publications (2)

Publication Number Publication Date
WO2003072046A2 WO2003072046A2 (en) 2003-09-04
WO2003072046A3 true WO2003072046A3 (en) 2005-03-10

Family

ID=27767540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005525 WO2003072046A2 (en) 2001-08-22 2003-02-24 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances

Country Status (9)

Country Link
US (1) US7622441B2 (en)
EP (2) EP2319540A1 (en)
JP (1) JP4878732B2 (en)
KR (1) KR100822498B1 (en)
AU (2) AU2003219863C1 (en)
CA (1) CA2477004C (en)
ES (1) ES2500117T3 (en)
IL (2) IL163667A0 (en)
WO (1) WO2003072046A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20070060500A1 (en) * 2000-08-22 2007-03-15 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US20090306228A1 (en) * 2000-11-14 2009-12-10 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20070066537A1 (en) * 2002-02-22 2007-03-22 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
WO2004062614A2 (en) * 2003-01-13 2004-07-29 New River Pharmaceuticals Inc. Carbohydrate conjugates to prevent abuse of controlled substances
ATE454169T1 (en) * 2003-03-13 2010-01-15 Controlled Chemicals Inc OXYCODONE CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED DURATION
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
ES2380622T5 (en) 2003-05-29 2018-05-30 Shire Llc Abuse resistant amphetamine compounds
CA2540678C (en) * 2003-09-30 2011-02-22 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US20050196455A1 (en) * 2003-10-27 2005-09-08 Jianbing Chen Suspension delivery system for the sustained and controlled local release of pharmaceuticals
KR20070087582A (en) * 2004-11-08 2007-08-28 뉴 리버 파마슈티칼스 인크. Synergistic effects of combined administration of mirtazapine and a stimulant compound
WO2006055729A1 (en) * 2004-11-16 2006-05-26 Transcutaneous Technologies Inc. Iontophoretic device and method for administering immune response-enhancing agents and compositions
JP2006296511A (en) * 2005-04-15 2006-11-02 Transcutaneous Technologies Inc External preparation, method for applying external preparation, iontophoresis device, and transdermal patch
AR057035A1 (en) * 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
JP2009509677A (en) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 Iontophoretic delivery of vesicle encapsulated active substances
US20070135754A1 (en) * 2005-09-30 2007-06-14 Hidero Akiyama Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same
US20070078375A1 (en) * 2005-09-30 2007-04-05 Transcutaneous Technologies Inc. Iontophoretic delivery of active agents conjugated to nanoparticles
KR20080080087A (en) * 2005-09-30 2008-09-02 티티아이 엘뷰 가부시키가이샤 Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
EP1965856A2 (en) * 2005-12-30 2008-09-10 Tti Ellebeau, Inc. Iontophoretic systems, devices, and methods of delivery of active agents to biological interface
CA2648659A1 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
MX2008014794A (en) * 2006-05-26 2009-04-08 Pharmacofore Inc Controlled release of phenolic opioids.
US20080207668A1 (en) * 2006-10-06 2008-08-28 New River Pharmaceuticals Inc. Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
EP2101571B1 (en) 2006-12-11 2011-05-18 Kempharm, Inc. Ornithine conjugates of amphetamine and processes for making and using the same
WO2008087803A1 (en) * 2007-01-16 2008-07-24 Hokkaido University Liposome preparation for iontophoresis having antioxidant component encapsulated therein
ATE552861T1 (en) * 2007-02-08 2012-04-15 Kempharm Inc POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND METHODS OF PRODUCTION AND USE
WO2008101187A2 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. Pro-drugs of peripheral phenolic opioid antagonists
EP2157970A1 (en) * 2007-05-18 2010-03-03 Tti Ellebeau, Inc. Transdermal delivery devices assuring an improved release of an active principle through a biological interface
JP2010187707A (en) * 2007-06-12 2010-09-02 Hokkaido Univ Liposome preparation for iontophoresis comprising insulin encapsulated therein
ES2692437T3 (en) * 2007-08-13 2018-12-03 Abuse Deterrent Pharmaceutical Llc Abuse-resistant drugs, method of use and method of preparation
US9023860B2 (en) 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
BRPI0918060A2 (en) * 2008-09-10 2015-12-01 Transcu Ltd apparatus and method of dispensing hpc viscous liquids on porous substrates, for example, continuous tissue based process.
ES2414856T3 (en) 2008-12-12 2013-07-23 Paladin Labs Inc. Narcotic drug formulations with decreased addiction potential
CA2750144C (en) 2008-12-31 2016-10-25 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
UA102916C2 (en) 2009-07-02 2013-08-27 Кемфарм, Інк. Composition based on conjugates of hydrocodone with benzoic acid, benzoic acid or heteroaryl carboxylic acid derivatives, prodrugs and method for treatment of abuses
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
US20120142720A1 (en) 2009-07-02 2012-06-07 Kempharm, Inc. Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2013527124A (en) 2009-07-17 2013-06-27 シャイア エルエルシー Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
BR112012008317A2 (en) 2009-09-17 2016-03-22 Upsher Smith Lab Inc sustained release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20130079364A1 (en) * 2010-04-21 2013-03-28 Signature Therapeutics, Inc. Peripheral Opioid Agonists and Peripheral Opioid Antagonists
ES2710617T3 (en) * 2010-04-21 2019-04-26 Signature Therapeutics Inc Compositions comprising enzymatically cleavable amphetamine prodrugs and inhibitors thereof
EP2663187B1 (en) 2011-01-11 2016-06-01 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
WO2012122422A2 (en) 2011-03-09 2012-09-13 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2016043698A1 (en) * 2014-09-15 2016-03-24 Inspirion Delivery Technologies, Llc Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2967424C (en) 2014-11-25 2023-05-02 Kempharm, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US9987269B2 (en) 2015-04-27 2018-06-05 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof
JP2019507181A (en) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド Pharmaceutical composition
JP7234130B2 (en) * 2017-03-17 2023-03-07 エリージウム セラピューティクス， インコーポレイテッド Polysubunit opioid prodrugs resistant to overdose and abuse
CN111107849B (en) 2017-07-20 2024-03-29 苏州润鑫达泰生物医药有限公司 Abuse resistant long-acting release opioid prodrugs
MX2020008706A (en) 2018-02-23 2020-09-25 Rhodes Tech Novel opioid compounds and uses thereof.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843696A (en) * 1972-09-05 1974-10-22 Syva Co Methadone analog compounds
US3878187A (en) * 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US4025501A (en) * 1975-03-20 1977-05-24 Syva Company Polypeptide propoxyphene derivatives for immunoassay reagents
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030091593A1 (en) * 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
DE1493824A1 (en) * 1964-01-27 1969-05-22 Hoffmann La Roche Process for the preparation of aminocarboxylic acid amides
CH406567A (en) 1964-02-10 1966-01-31 Inventio Ag Device for controlling the setpoint value during the deceleration process in elevators with speed-controlled drives
GB1112347A (en) 1965-08-20 1968-05-01 Pierre Wirth Salts of organic bases with n-carbamyl-l-glutamic acid
US3846399A (en) 1969-04-10 1974-11-05 Merck & Co Inc Process for controlled stepwise synthesis of polypeptides
US3975342A (en) 1972-05-15 1976-08-17 Biological Developments, Inc. Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto
US3884898A (en) 1972-08-18 1975-05-20 Syva Co Normorphine derivatives bonded to proteins
US3998799A (en) 1973-11-02 1976-12-21 Interx Research Corporation Novel, transient pro-drug forms of l-dopa
US4040907A (en) 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
GB1592552A (en) 1976-12-10 1981-07-08 Inst Nat Sante Rech Med Pseudopeptides used as medicaments
US4356166A (en) 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
HU185535B (en) 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
US4457907A (en) 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4650675A (en) 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
ATE60340T1 (en) 1984-10-19 1991-02-15 Battelle Memorial Institute MICROORGANISM DEGRADABLE POLYPEPTIDE AND ITS USE FOR PROGRESSIVE DELIVERY OF MEDICATIONS.
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US4863735A (en) 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
IN165717B (en) 1986-08-07 1989-12-23 Battelle Memorial Institute
DK406686D0 (en) 1986-08-26 1986-08-26 Hans Bundgaard carboxylic acid derivatives
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5026827A (en) 1988-09-02 1991-06-25 Matsushita Electric Industrial Co., Ltd. Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5767227A (en) 1989-11-03 1998-06-16 Lotus Biochemical Corp. Iodothyronine polymers
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
DE69103503T2 (en) 1990-09-28 1995-01-05 Mercian Corp Adriamycin derivatives.
US5238714A (en) 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2096495C (en) 1992-06-16 2002-07-09 Kathy Palmer Ordonez Dual analyte immunoassay
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
GB9215780D0 (en) 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
US6093391A (en) 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
IL107400A0 (en) 1992-11-10 1994-01-25 Cortech Inc Bradykinin antagonists
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO1995012604A1 (en) 1993-11-05 1995-05-11 Aktiebolaget Astra Novel amino acid derivatives
WO1995014033A1 (en) 1993-11-19 1995-05-26 Aktiebolaget Astra Novel dipeptide derivatives
GB9401891D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5847436A (en) * 1994-03-18 1998-12-08 Kabushiki Kaisha Tokai Rika Denki Seisakusho Bipolar transistor having integrated thermistor shunt
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5910569A (en) 1994-11-22 1999-06-08 Lotus Biochemical Corporation Iodothyronine polymers
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5710256A (en) * 1995-04-03 1998-01-20 Biosite Diagnostics Incorporated Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
WO1996040123A1 (en) 1995-06-07 1996-12-19 Swadesh Joel K Antigen-processing cell-targeted conjugates
US5762909A (en) 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
US5851536A (en) 1995-11-22 1998-12-22 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US5922736A (en) 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
GB9606975D0 (en) 1996-04-02 1996-06-05 Univ Birmingham Anti-tumor agent
US6030941A (en) 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US5970477A (en) * 1996-07-15 1999-10-19 Bellsouth Intellectual Property Management Corporation Method and system for allocating costs in a distributed computing network
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
US6013633A (en) 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE69818987T2 (en) 1997-05-21 2004-07-29 The Board Of Trustees Of The Leland Stanford Junior University, Stanford COMPOSITION AND METHOD FOR DELAYING THE TRANSPORT BY BIOLOGICAL MEMBRANES
TW460478B (en) 1997-08-15 2001-10-21 Chugai Pharmaceutical Co Ltd Phenethylamine derivatives
CA2312975C (en) 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
BR9813826A (en) * 1997-12-22 2000-10-10 Euro Celtique Sa Potential for abusive use of oral administration of analgesic opioids
EP1053238B1 (en) 1998-01-29 2005-12-28 Monash University Therapeutic compounds
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
JP2002540073A (en) * 1999-03-10 2002-11-26 ロータス バイオケミカル コーポレイション Use of protein conformation for protection and release of chemical compounds
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001008661A2 (en) * 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Opioid sustained-released formulation
SI1299104T1 (en) * 2000-02-08 2009-10-31 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US20020098999A1 (en) 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
US6992076B2 (en) 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
WO2002028882A1 (en) 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
ATE454169T1 (en) 2003-03-13 2010-01-15 Controlled Chemicals Inc OXYCODONE CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED DURATION

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843696A (en) * 1972-09-05 1974-10-22 Syva Co Methadone analog compounds
US3878187A (en) * 1972-09-11 1975-04-15 Syva Co Polypeptide derivatives of amphetamine and analogs for immunoassays
US4025501A (en) * 1975-03-20 1977-05-24 Syva Company Polypeptide propoxyphene derivatives for immunoassay reagents
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US20030091593A1 (en) * 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles

Also Published As

Publication number Publication date
KR20040095228A (en) 2004-11-12
AU2003219863B2 (en) 2008-07-31
CA2477004A1 (en) 2003-09-04
EP1531844A4 (en) 2007-06-13
IL163667A0 (en) 2005-12-18
EP1531844A2 (en) 2005-05-25
AU2003219863C1 (en) 2009-03-05
JP2005524648A (en) 2005-08-18
AU2008229978A1 (en) 2008-11-06
WO2003072046A2 (en) 2003-09-04
EP2319540A1 (en) 2011-05-11
AU2008229978B2 (en) 2012-03-22
KR100822498B1 (en) 2008-04-16
EP1531844B1 (en) 2014-08-20
ES2500117T3 (en) 2014-09-30
AU2003219863A1 (en) 2003-09-09
US7622441B2 (en) 2009-11-24
CA2477004C (en) 2011-05-10
US20050080012A1 (en) 2005-04-14
JP4878732B2 (en) 2012-02-15
IL163667A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
WO2003072046A3 (en) Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
WO2003080022A3 (en) Analgesics for nasal administration
WO1999053910A3 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
DK1317419T3 (en) Cyanophenoxycarboxylic acid compounds and compositions to deliver active agents
HUP0102250A2 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
Ghosh et al. Drug delivery to the oral cavity: molecules to market
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003065982A3 (en) Engineering absorption of therapeutic compounds via colonic transporters
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2008064192A3 (en) Modified release analgesic suspensions
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
WO2005032567A3 (en) Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
GEP20125684B (en) Dipeptidyl peptidase inhibitors weekly administration
WO2004032849A3 (en) Methods of administering fgf18
ATE413865T1 (en) COMPOSITIONS WITH ALPHAHYDROXY ACID ESTERS FOR THE RELEASE OF ACTIVE INGREDIENTS AND METHODS OF USE THEREOF
GB0406282D0 (en) Therapeutic compounds
WO2001013933A3 (en) Agents for the enhanced oxygen delivery in mammals
RS52966B (en) Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
WO2002015876A3 (en) Amorphous carrier materials for drug delivery
PE20030830A1 (en) AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL CAVITY AND PHARYNGEAL
PL377683A1 (en) Therapeutic system comprising amoxicillin and clavulanic acid
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2477004

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 163667

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10923257

Country of ref document: US

Ref document number: 1020047013136

Country of ref document: KR

Ref document number: 2003570793

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003219863

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 01300/KOLNP/2004

Country of ref document: IN

Ref document number: 1300/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003716144

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038087162

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020047013136

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003716144

Country of ref document: EP